
Stephen Ringle
Founder & CEO of Nome, an AI-enabled techbio building custom therapeutics for ultra-rare diseases, and founder of the Kizuna Foundation; rare disease patient advocate.
1
APPEARANCES
1
PODCASTS
012
DEC 30
JAN 6
JAN 13
JAN 20
JAN 27
FEB 3
FEB 10
FEB 17
FEB 24
MAR 3
MAR 10
MAR 17
MAR 24
MAR 31
APR 7
APR 14
APR 21
APR 28
MAY 5
MAY 12
MAY 19
MAY 26
JUN 2
JUN 9
JUN 16
JUN 23
JUN 30
JUL 7
JUL 14
JUL 21
JUL 28
AUG 4
AUG 11
AUG 18
AUG 25
SEP 1
SEP 8
SEP 15
SEP 22
SEP 29
OCT 6
OCT 13
OCT 20
OCT 27
NOV 3
NOV 10
NOV 17
NOV 24
DEC 1
DEC 8
DEC 15
DEC 22
DEC 29
JAN 5
JAN 12
JAN 19
JAN 26
FEB 2
FEB 9
FEB 16
FEB 23
MAR 2
MAR 9
MAR 16
MAR 23
MAR 30
APR 6
APR 13
APR 20
APR 27
MAY 4
MAY 11
MAY 18
MAY 25
JUN 1
JUN 8
JUN 15
JUN 22
JUN 29
JUL 6
JUL 13
JUL 20
JUL 27
AUG 3
AUG 10
AUG 17
AUG 24
AUG 31
SEP 7
SEP 14
SEP 21
SEP 28
OCT 5
OCT 12
OCT 19
OCT 26
NOV 2
Sep 24, 2026
Enabling Patient Foundations to Build the Next Generation of Genetic Therapies
18:49
19:00
19:04
D
18:28Daniel LevineHOST
Can you walk us through a specific patient journey with Nome from genetic diagnosis to a, a treatment plan and, and into manufacturing and clinical execution? What, what's the process? What does that look like?

Stephen RingleGUEST
They go on our website, which is www.nome.bio, and they submit their genetic information and as much clinical detail as they, as they can.

Stephen RingleGUEST
We're, we're HIPAA compliant, so, you know, all the data is highly protected.

Stephen RingleGUEST
We process it in the type of report that I was sharing with you that has these, um, tiered insights about what might be appropriate for that family.
D
23:08Daniel LevineHOST
A-and in terms of your customers, are they generally individual families, or are, are they patient organizations, and how do you get paid?